X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SHASUN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SHASUN PHARMA SANOFI INDIA/
SHASUN PHARMA
 
P/E (TTM) x 37.5 123.9 30.3% View Chart
P/BV x 8.1 8.5 94.9% View Chart
Dividend Yield % 1.1 0.2 477.9%  

Financials

 SANOFI INDIA   SHASUN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
SHASUN PHARMA
Mar-14
SANOFI INDIA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,56094 4,840.8%   
Low Rs4,40046 9,649.1%   
Sales per share (Unadj.) Rs1,028.5214.2 480.2%  
Earnings per share (Unadj.) Rs129.05.3 2,416.9%  
Cash flow per share (Unadj.) Rs186.015.8 1,175.6%  
Dividends per share (Unadj.) Rs68.001.00 6,800.0%  
Dividend yield (eoy) %1.51.4 106.1%  
Book value per share (Unadj.) Rs753.653.3 1,412.8%  
Shares outstanding (eoy) m23.0356.62 40.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,334.7%   
Avg P/E ratio x34.713.1 265.2%  
P/CF ratio (eoy) x24.14.4 545.2%  
Price / Book Value ratio x5.91.3 453.6%  
Dividend payout %52.718.7 281.4%   
Avg Mkt Cap Rs m103,1743,958 2,606.9%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5922,164 166.0%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68612,127 195.3%  
Other income Rs m708229 308.7%   
Total revenues Rs m24,39412,356 197.4%   
Gross profit Rs m5,2811,009 523.4%  
Depreciation Rs m1,313594 221.2%   
Interest Rs m15415 3.6%   
Profit before tax Rs m4,661230 2,029.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-73 -2,325.4%   
Profit after tax Rs m2,970302 983.1%  
Gross profit margin %22.38.3 268.0%  
Effective tax rate %36.3-31.7 -114.6%   
Net profit margin %12.52.5 503.3%  
BALANCE SHEET DATA
Current assets Rs m15,6736,884 227.7%   
Current liabilities Rs m6,6788,456 79.0%   
Net working cap to sales %38.0-13.0 -293.0%  
Current ratio x2.30.8 288.3%  
Inventory Days Days7662 123.3%  
Debtors Days Days22108 20.7%  
Net fixed assets Rs m8,0984,970 162.9%   
Share capital Rs m230113 203.3%   
"Free" reserves Rs m17,0882,875 594.4%   
Net worth Rs m17,3563,020 574.7%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m25,40013,347 190.3%  
Interest coverage x311.71.6 20,068.3%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.9 102.6%   
Return on assets %11.85.4 218.7%  
Return on equity %17.110.0 171.1%  
Return on capital %26.913.3 202.2%  
Exports to sales %24.546.4 52.8%   
Imports to sales %28.014.2 196.4%   
Exports (fob) Rs m5,8015,622 103.2%   
Imports (cif) Rs m6,6271,728 383.6%   
Fx inflow Rs m7,1455,843 122.3%   
Fx outflow Rs m6,8462,173 315.0%   
Net fx Rs m2993,669 8.1%   
CASH FLOW
From Operations Rs m3,226398 811.4%  
From Investments Rs m-1,555-1,635 95.1%  
From Financial Activity Rs m-1,8181,309 -138.9%  
Net Cashflow Rs m-14771 -206.5%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 3.6 400.0%  
FIIs % 14.6 17.6 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 39.6 26.5%  
Shareholders   15,184 20,750 73.2%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS